Natural killer cell biology: An update and future directions - 02/09/13
, Jun Hasegawa, PhDAbstract |
Natural killer (NK) cells constitute a minor subset of normal lymphocytes that initiate innate immune responses toward tumor and virus-infected cells. They can mediate spontaneous cytotoxicity toward these abnormal cells and rapidly secrete numerous cytokines and chemokines to promote subsequent adaptive immune responses. Significant progress has been made in the past 2 decades to improve our understanding of NK cell biology. Here we review recent discoveries, including a better comprehension of the “education” of NK cells to achieve functional competence during their maturation and the discovery of “memory” responses by NK cells, suggesting that they might also contribute to adaptive immunity. The improved understanding of NK cell biology has forged greater awareness that these cells play integral early roles in immune responses. In addition, several promising clinical therapies have been used to exploit NK cell functions in treating patients with cancer. As our molecular understanding improves, these and future immunotherapies should continue to provide promising strategies to exploit the unique functions of NK cells to treat cancer, infections, and other pathologic conditions.
Le texte complet de cet article est disponible en PDF.Key words : Natural killer cell, killer cell immunoglobulin-like receptors, innate immunity, immune memory, antibody-dependent cellular cytotoxicity, cancer, viral infection, hematopoietic stem cell transplantation, immunomodulatory drugs, IFN-γ
Abbreviations used : ADCC, AML, CAR, HSC, ILC, ITIM, KIR, MCMV, MHC-I, MM, NCR, NK, PD-1, SRIR
Plan
| Supported by National Institutes of Health grants CA083859 (to K.S.C.) and CA06927 (FCCC) and a Health Research Formula Fund (CURE) grant from the Pennsylvania Department of Health. The department specifically disclaims responsibility for any analyses, interpretations, or conclusions. J.H. was supported by Daiichi Sankyo Co, Tokyo, Japan. |
|
| Disclosure of potential conflict of interest: K. S. Campbell has received grants from the National Institutes of Health, the Pennsylvania Department of Health, and Bristol Meyers Squibb; has consultant arrangements with Bristol Meyers Squibb; has a patent for genetically modified human natural killer cell lines; and has received royalties from Springer Press. J. Hasegawa has received financial and travel support from Daiichi Sankyo Co. |
Vol 132 - N° 3
P. 536-544 - septembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
